Bicara Therapeutics Common Stock Market Value
| BCAX Stock | 16.91 0.32 1.93% |
| Symbol | Bicara |
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bicara Therapeutics. Projected growth potential of Bicara fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Bicara Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Bicara Therapeutics is measured differently than its book value, which is the value of Bicara that is recorded on the company's balance sheet. Investors also form their own opinion of Bicara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Bicara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bicara Therapeutics' market value can be influenced by many factors that don't directly affect Bicara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Bicara Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bicara Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Bicara Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Bicara Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Bicara Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Bicara Therapeutics.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in Bicara Therapeutics on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding Bicara Therapeutics Common or generate 0.0% return on investment in Bicara Therapeutics over 90 days. Bicara Therapeutics is related to or competes with Kura Oncology, Septerna Common, Eyepoint Pharmaceuticals, ProKidney Corp, Prime Medicine, Tango Therapeutics, and Phathom Pharmaceuticals. More
Bicara Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Bicara Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Bicara Therapeutics Common upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.33 | |||
| Information Ratio | 0.0196 | |||
| Maximum Drawdown | 18.88 | |||
| Value At Risk | (4.85) | |||
| Potential Upside | 6.05 |
Bicara Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bicara Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Bicara Therapeutics' standard deviation. In reality, there are many statistical measures that can use Bicara Therapeutics historical prices to predict the future Bicara Therapeutics' volatility.| Risk Adjusted Performance | 0.034 | |||
| Jensen Alpha | 0.11 | |||
| Total Risk Alpha | (0.14) | |||
| Sortino Ratio | 0.0224 | |||
| Treynor Ratio | 0.4032 |
Bicara Therapeutics January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.034 | |||
| Market Risk Adjusted Performance | 0.4132 | |||
| Mean Deviation | 3.04 | |||
| Semi Deviation | 3.26 | |||
| Downside Deviation | 3.33 | |||
| Coefficient Of Variation | 2802.52 | |||
| Standard Deviation | 3.81 | |||
| Variance | 14.54 | |||
| Information Ratio | 0.0196 | |||
| Jensen Alpha | 0.11 | |||
| Total Risk Alpha | (0.14) | |||
| Sortino Ratio | 0.0224 | |||
| Treynor Ratio | 0.4032 | |||
| Maximum Drawdown | 18.88 | |||
| Value At Risk | (4.85) | |||
| Potential Upside | 6.05 | |||
| Downside Variance | 11.09 | |||
| Semi Variance | 10.62 | |||
| Expected Short fall | (3.57) | |||
| Skewness | 0.437 | |||
| Kurtosis | 0.3759 |
Bicara Therapeutics Backtested Returns
At this stage we consider Bicara Stock to be somewhat reliable. Bicara Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0357, which signifies that the company had a 0.0357 % return per unit of standard deviation over the last 3 months. We have found twenty-nine technical indicators for Bicara Therapeutics Common, which you can use to evaluate the volatility of the firm. Please confirm Bicara Therapeutics' mean deviation of 3.04, and Risk Adjusted Performance of 0.034 to double-check if the risk estimate we provide is consistent with the expected return of 0.14%. Bicara Therapeutics has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.31, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Bicara Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Bicara Therapeutics is expected to be smaller as well. Bicara Therapeutics right now shows a risk of 3.81%. Please confirm Bicara Therapeutics coefficient of variation, semi variance, period momentum indicator, as well as the relationship between the treynor ratio and daily balance of power , to decide if Bicara Therapeutics will be following its price patterns.
Auto-correlation | -0.13 |
Insignificant reverse predictability
Bicara Therapeutics Common has insignificant reverse predictability. Overlapping area represents the amount of predictability between Bicara Therapeutics time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Bicara Therapeutics price movement. The serial correlation of -0.13 indicates that less than 13.0% of current Bicara Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.13 | |
| Spearman Rank Test | -0.26 | |
| Residual Average | 0.0 | |
| Price Variance | 0.43 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| VTI | Vanguard Total Stock | |
| RIOT | Riot Blockchain | |
| TSLA | Tesla Inc |
Additional Tools for Bicara Stock Analysis
When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.